EGFR and Hepatic fibrosis: This activation triggers HSC transformation into myofibroblasts, inhibiting ECM degradation (46).Molecular docking simulations suggest that ginsenoside Rh2—a bioactive constituent of PZH—may attenuate hepatic fibrosis through modulation of the EGFR/JAK1/STAT3 signaling axis.